Alkermes Plc news

   Watch this stock
Showing stories 1 - 10 of about 91   

Articles published

ALKS 48.58 -1.00 (-2.02%)
price chart
Alkermes PLC (ALKS) Given "Buy" Rating at Cowen and Company
Alkermes PLC logo Cowen and Company reiterated their buy rating on shares of Alkermes PLC (NASDAQ:ALKS) in a research note published on Friday morning.
Alkermes PLC (ALKS) CMO Elliot Ehrich Sells 5000 Shares of Stock  BBNS
Latest Stock's Price Updates: Alkermes plc (NASDAQ:ALKS)
In the past trading session, Alkermes plc (NASDAQ:ALKS) highlighted downward shift of -2.78% or -1.42 points to $49.58. The company traded a volume of 1.05 million shares over average volume of 844.64 thousand shares.
Elliot Ehrich Sells 5000 Shares of Alkermes PLC (ALKS) Stock
Alkermes PLC logo Alkermes PLC (NASDAQ:ALKS) CMO Elliot Ehrich sold 5,000 shares of the business's stock in a transaction that occurred on Thursday, September 22nd.
Alkermes PLC (ALKS) Given Buy Rating at Cowen and Company  Community Financial News
Summary of Insider Trading: Alkermes plc (NASDAQ:ALKS)  Street Updates
Alkermes Launches Competitive Grants Program to Support People Affected by ...
DUBLIN--(BUSINESS WIRE)--Alkermes plc (NASDAQ: ALKS), a global biopharmaceutical company developing medicines for the treatment of central nervous system (CNS) diseases, such as schizophrenia, major depressive disorder and multiple sclerosis, ...
Alkermes plc Price Volatility Hits An Escalated Level
This is a proprietary price volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for Alkermes plc (NASDAQ:ALKS) . We also look at broad measures of the S&P 500 and Nasdaq 100 indices as well as ...
Alkermes plc (ALKS) Tops Q2 EPS by 9c
Alkermes plc (NASDAQ: ALKS) reported Q2 EPS of ($0.01), $0.09 better than the analyst estimate of ($0.10). Revenue for the quarter came in at $195.2 million versus the consensus estimate of $174.15 million.
Alkermes Plc (ALKS) Richard Pops on Q2 2016 Results - Earnings Call Transcript  Seeking Alpha
Alkermes plc Reports Financial Results for the Year Ended Dec. 31, 2015 and ...
Alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (CNS) diseases.
Alkermes Plc (ALKS) Richard F. Pops on Q4 2015 Results - Earnings Call ...  Seeking Alpha
Alkermes Plc (ALKS) Ascent Sends Options Volume to the Moon
A number of drug stocks are making moves higher, and biotech Alkermes Plc (NASDAQ:ALKS) is no exception amid unsubstantiated takeover talk.
Top Earnings to Watch for: Alkermes plc (NASDAQ:ALKS)
Alkermes plc (NASDAQ:ALKS) rose 0.16 per cent to reach at the trading price of $49.77 as it is set to release its next quarterly earnings report on October 27, 2016.
Snapshot of Avg. Earnings Forecasts: Alkermes plc (NASDAQ:ALKS)  WsNews 4investors
Form 8-K/A Alkermes plc. For: May 25
Explanatory Note: Alkermes plc (the “Company”) hereby amends Item 5.02(d) of its Current Report on Form 8-K dated May 26, 2016 for the purpose of describing a grant made to a director in connection with the event triggering such Item 5.02(d).